Evolva shareholders approve all Board proposals in AGM
Reinach, Switzerland, 9 May 2012 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.
A total of 69 shareholders were present at the meeting which took place in Basel today. 98,905,326 shares were represented, or 57% of the total number of shares issued (173,318,279). A detailed overview of the agenda items and the proposals is available on the Evolva website.
It was announced during the meeting that Sir Tom McKillop will be succeeding Erich Schlick as Chairman of the Board of Directors. Erich Schlick will remain on the Board. Sir Tom has been on Evolva’s Board of Directors since 2010. In his long career he has held senior positions in pharma, industrial biotechnology (ICI) and in agricultural chemicals (Zeneca). As such, he has extensive knowledge and experience in all fields in which Evolva is active.
– Ends –
About Evolva Holding SA
Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. We are active in consumer healthcare and nutrition as well as in pharma. In both areas we have partnered projects as well as proprietary programmes. For more information see www.evolva.com.
|Neil Goldsmith, CEO||Jakob Dynnes Hansen, CFO||Paul Verbraeken, IR|
|+ 41 61 485 2005||+ 41 61 485 2034||+ 41 61 485 2035|
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.